Details for New Drug Application (NDA): 209330
✉ Email this page to a colleague
NDA 209330 describes CARFILZOMIB, which is a drug marketed by Apotex, Breckenridge, and Dr Reddys, and is included in four NDAs. Additional details are available on the CARFILZOMIB profile page.
The generic ingredient in CARFILZOMIB is carfilzomib. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carfilzomib profile page.
The generic ingredient in CARFILZOMIB is carfilzomib. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the carfilzomib profile page.
Summary for 209330
| Tradename: | CARFILZOMIB |
| Applicant: | Breckenridge |
| Ingredient: | carfilzomib |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAVENOUS | Strength | 10MG/VIAL | ||||
| Approval Date: | Jun 11, 2021 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INTRAVENOUS | Strength | 60MG/VIAL | ||||
| Approval Date: | Jun 11, 2021 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
